ES2646590T3 - Polinucleótidos para el tratamiento de tumores positivos para polipéptidos víricos oncogénicos - Google Patents
Polinucleótidos para el tratamiento de tumores positivos para polipéptidos víricos oncogénicos Download PDFInfo
- Publication number
- ES2646590T3 ES2646590T3 ES13740950.4T ES13740950T ES2646590T3 ES 2646590 T3 ES2646590 T3 ES 2646590T3 ES 13740950 T ES13740950 T ES 13740950T ES 2646590 T3 ES2646590 T3 ES 2646590T3
- Authority
- ES
- Spain
- Prior art keywords
- deletion
- point mutation
- seq
- mut
- oncogenic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10041—Use of virus, viral particle or viral elements as a vector
- C12N2710/10042—Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20071—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261590089P | 2012-01-24 | 2012-01-24 | |
| US201261590089P | 2012-01-24 | ||
| PCT/US2013/022696 WO2013112549A1 (en) | 2012-01-24 | 2013-01-23 | Polynucleotides for treating oncogenic viral polypeptide positive tumors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2646590T3 true ES2646590T3 (es) | 2017-12-14 |
Family
ID=48873849
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES13740950.4T Active ES2646590T3 (es) | 2012-01-24 | 2013-01-23 | Polinucleótidos para el tratamiento de tumores positivos para polipéptidos víricos oncogénicos |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US9492526B2 (enExample) |
| EP (2) | EP2806889B1 (enExample) |
| JP (2) | JP6219849B2 (enExample) |
| KR (1) | KR102195196B1 (enExample) |
| CN (2) | CN104159607A (enExample) |
| DK (1) | DK2806889T3 (enExample) |
| ES (1) | ES2646590T3 (enExample) |
| HK (1) | HK1203833A1 (enExample) |
| IN (1) | IN2014DN06118A (enExample) |
| WO (1) | WO2013112549A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS60937B1 (sr) | 2014-11-13 | 2020-11-30 | Univ Geneve | Tri-segmentirani arenavirusi kao vektori za vakcinu |
| CN115197965A (zh) | 2015-06-10 | 2022-10-18 | 霍欧奇帕生物科技有限公司 | Hpv疫苗 |
| CN108779472B (zh) | 2015-11-04 | 2022-09-09 | 霍欧奇帕生物科技有限公司 | 针对乙型肝炎病毒的疫苗 |
| EP3373959B1 (en) | 2015-11-12 | 2022-06-29 | Hookipa Biotech GmbH | Arenavirus particles as cancer vaccines |
| KR102833333B1 (ko) | 2016-01-08 | 2025-07-11 | 니코데 테라퓨틱스 에이에스에이 | 치료적 항암 네오에피토프 백신 |
| GB201605210D0 (en) | 2016-03-29 | 2016-05-11 | Oxford Immunotec Ltd | Assay |
| EP3463577A4 (en) * | 2016-06-03 | 2019-12-04 | Etubics Corporation | COMPOSITIONS AND METHODS FOR TREATING DISEASES ASSOCIATED WITH HUMAN PAPILLOMVIRUS (HPV) |
| CN106655327A (zh) * | 2016-10-18 | 2017-05-10 | 云南中烟工业有限责任公司 | 一种压缩式充电装置 |
| CN117370603A (zh) | 2016-11-11 | 2024-01-09 | 谷歌有限责任公司 | 基于用户装置的消费模式来修改视频内容在用户装置上的呈现的方法、系统和介质 |
| US12404306B2 (en) | 2018-03-06 | 2025-09-02 | Precigen, Inc. | Human papillomavirus vaccines and uses of the same |
| EP4121567B1 (en) * | 2020-03-16 | 2025-12-31 | The University of North Carolina at Chapel Hill | COMPOSITIONS AND METHODS FOR THE SELECTIVE DETECTION OF TUMOR-DERIVED VIRAL DNA |
| KR102712588B1 (ko) * | 2020-05-25 | 2024-10-02 | (주)진매트릭스 | 사람 파필로마바이러스의 구조적으로 변형된 키메라 폴리펩타이드 및 그 폴리펩타이드를 포함하는 재조합 단백질 및 그 단백질의 용도 |
| CA3178325A1 (en) * | 2020-05-25 | 2021-12-02 | Soo Ok Kim | Structurally modified chimeric polypeptide of human papillomavirus, recombinant protein comprising same polypeptide, and use of same protein |
| CN116425839A (zh) * | 2023-04-03 | 2023-07-14 | 深圳锦时生物科技有限公司 | 人乳头瘤病毒多肽及其应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9717953D0 (en) * | 1997-08-22 | 1997-10-29 | Smithkline Beecham Biolog | Vaccine |
| ATE283915T1 (de) * | 1998-05-26 | 2004-12-15 | Inst Of Molecul & Cell Biology | Polypeptide aus dem creb-bindenden protein und verwandten protein p-300 zur verwendung bei der transkriptionellen regulation |
| US7223408B2 (en) | 2002-10-03 | 2007-05-29 | Wyeth Holdings Corporation | Human papillomavirus polypeptides and immunogenic compositions |
| BRPI0810305A2 (pt) * | 2007-05-15 | 2018-07-10 | Transgene Sa | "vetor, molécula de ácido nucléico substancialmente isolada, célula hospedeira, composição farmacêutica, uso de uma molécula de ácido nucléico, uso de um vetor, uso de uma célula hospedeira e uso de uma composição" |
| US20120244173A1 (en) * | 2009-04-28 | 2012-09-27 | Tzyy-Choou Wu | Compositions and Methods for Enhancing Antigen-Specific Immune Responses |
| CN102002105B (zh) * | 2009-09-03 | 2013-01-23 | 中国疾病预防控制中心病毒病预防控制所 | Hpv 16型e7e6融合蛋白基因、表达载体、方法、细胞和用途 |
-
2013
- 2013-01-23 JP JP2014554791A patent/JP6219849B2/ja active Active
- 2013-01-23 DK DK13740950.4T patent/DK2806889T3/da active
- 2013-01-23 WO PCT/US2013/022696 patent/WO2013112549A1/en not_active Ceased
- 2013-01-23 CN CN201380012419.2A patent/CN104159607A/zh active Pending
- 2013-01-23 EP EP13740950.4A patent/EP2806889B1/en active Active
- 2013-01-23 HK HK15104469.7A patent/HK1203833A1/xx unknown
- 2013-01-23 US US14/373,844 patent/US9492526B2/en active Active
- 2013-01-23 CN CN201910216555.2A patent/CN110042110A/zh active Pending
- 2013-01-23 EP EP17185609.9A patent/EP3269387B1/en active Active
- 2013-01-23 KR KR1020147023589A patent/KR102195196B1/ko active Active
- 2013-01-23 IN IN6118DEN2014 patent/IN2014DN06118A/en unknown
- 2013-01-23 ES ES13740950.4T patent/ES2646590T3/es active Active
-
2016
- 2016-09-06 US US15/257,198 patent/US9969779B2/en active Active
-
2017
- 2017-09-28 JP JP2017188121A patent/JP6655051B2/ja active Active
-
2018
- 2018-04-11 US US15/950,819 patent/US20180237477A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2015506179A (ja) | 2015-03-02 |
| EP2806889A1 (en) | 2014-12-03 |
| WO2013112549A1 (en) | 2013-08-01 |
| EP3269387B1 (en) | 2019-07-17 |
| US20150023996A1 (en) | 2015-01-22 |
| EP3269387A1 (en) | 2018-01-17 |
| US9969779B2 (en) | 2018-05-15 |
| EP2806889A4 (en) | 2016-04-20 |
| EP2806889B1 (en) | 2017-08-16 |
| US20160376324A1 (en) | 2016-12-29 |
| KR20140131929A (ko) | 2014-11-14 |
| CN104159607A (zh) | 2014-11-19 |
| CN110042110A (zh) | 2019-07-23 |
| JP6655051B2 (ja) | 2020-02-26 |
| HK1203833A1 (en) | 2015-11-06 |
| US9492526B2 (en) | 2016-11-15 |
| US20180237477A1 (en) | 2018-08-23 |
| JP6219849B2 (ja) | 2017-10-25 |
| IN2014DN06118A (enExample) | 2015-08-14 |
| KR102195196B1 (ko) | 2020-12-28 |
| JP2018038405A (ja) | 2018-03-15 |
| DK2806889T3 (da) | 2017-11-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9969779B2 (en) | Polynucleotides for treating oncogenic viral polypeptide positive tumors | |
| Dai et al. | Modified vaccinia virus Ankara triggers type I IFN production in murine conventional dendritic cells via a cGAS/STING-mediated cytosolic DNA-sensing pathway | |
| US12584146B2 (en) | Synthetic modified vaccinia Ankara (SMVA) based coronavirus vaccines | |
| US20250109181A1 (en) | LAMP Constructs | |
| EP1668142A1 (en) | Modified vaccinia virus ankara (mva) mutant and use thereof | |
| US20240415951A1 (en) | Lentiviral vector for expression of human papillomavirus (hpv) antigens and its implementation in the treatment of hpv induced cancers | |
| US20250066427A1 (en) | Therapeutic papilloma virus vaccines | |
| CA2774154A1 (en) | Compositions and methods for improving immune responses to hiv vaccination | |
| AU2016242460B2 (en) | Recombinant mumps virus Jeryl Lynn 2 based vaccine | |
| CA3111663A1 (en) | Herv-k-derived antigens as shared tumor antigens for anti-cancer vaccine | |
| US10980873B2 (en) | Use of a genetically modified infectious measles virus with enhanced pro-apoptotic properties (MV-deltaC virus) in cancer therapy | |
| CN121203032A (zh) | 包含癌抗原的改良lamp构建物 | |
| US20220307054A1 (en) | Modulation of t cell responses by ul18 of human cytomegalovirus | |
| Chiozzini et al. | CD8+ T cell immunogenicity induced by endogenous EVs engineered by antigens fused to a truncated Nefmut EV-anchoring protein | |
| EP4547851A1 (en) | Epstein-barr-virus vaccine | |
| US20190282641A1 (en) | Generation of Tumor Endothelium Specific Viruses | |
| JP2014198736A (ja) | 機械的表皮破壊を介したポックスウイルスベクターによるワクチン接種 | |
| Detu | Development of New Neural Stem Cell-Based Tumor-Targeted Gene Therapy Approaches |